ARTICLE | Clinical News

Cellcor regulatory update

September 27, 1993 7:00 AM UTC

Cellcor received FDA approval to recover costs associated with a compassionate use protocol for patients receiving Cellcor's Autolymphocyte Therapy (ALT) for metastatic renal cell carcinoma (mRCC). The 190 patients eligible to participate already have received ALT in a commercial or research setting, Cellcor said. ...